Fenfluramine

Fenfluramine was withdrawn from market as an appetite suppressant in 1997 due to cardiotoxicity (valvular heart disease and pulmonary hypertension). Reintroduced in 2020 for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome at lower therapeutic doses. Available only through restricted REMS program requiring cardiac monitoring via echocardiogram. At high recreational doses (80-400 mg), can produce psychedelic effects resembling LSD, along with euphoria, sedation, anxiety, and adverse reactions. Contraindicated in patients with history of cardiac disease.

Also known as: Pondimin, Fintepla, Ponderax, Adifax, Rotondin, DL-fenfluramine

Classification

Chemical: Amphetamine
Chemical: Medicine
Chemical: Phenethylamine
Psychoactive: Depressant
Psychoactive: Psychedelic
Tag: Anticonvulsant
Tag: Habit-Forming

Effects

Sedation
Lethargy
Nausea
Loss Of Appetite
Fatigue
Incoordination
Decreased Arousal
Anxiety
Euphoria
Time Distortion
Dizziness
Cognitive Impairment
Appetite Suppression
Hallucinations
Dulled Perception
Color Enhancement
Visual Distortion
Internal Hallucination

Routes of Administration

Oral

Dosage

Threshold: 2 mg
Light: 2-5 mg
Common: 6-20 mg
Strong: 20-40 mg
Heavy: 40 mg

Duration

Onset: 0.5-1 h
Comeup: 1-2 h
Peak: 3-5 h
Offset: 6-12 h
After Effects: 12-24 h
Total Duration: 8-12 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

dose.wiki

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu